-
401
Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12)
Published 2018-08-01Get full text
Article -
402
Comparing propofol anaesthesia guided by Bispectral Index monitoring and frontal EEG wave analysis with standard monitoring in laparoscopic surgery: protocol for the ‘EEG in General Anaesthesia - More Than Only a Bispectral Index’ Trial, a multicentre, double-blind, randomised controlled trial
Published 2022-06-01“…We hypothesise that quality of recovery (QoR) in patients undergoing laparoscopic surgery is better, if propofol is titrated by anaesthesia practitioners able to interpret the EEG.Methods and analysis This is a multicentre, double-blind (patients and outcome assessors) randomised controlled trial taking place in four Swiss hospitals. …”
Get full text
Article -
403
Research on Density Peak Clustering Color-Separation Algorithm Based on SOM Neural Network
Published 2025-01-01Subjects: Get full text
Article -
404
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)
Published 2022-07-01“…Here, we summarise an ethically approved protocol for a double-blind, randomised controlled trial investigating the effect of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23) on pneumococcal nasopharyngeal colonisation acquisition, density and duration using experimental human pneumococcal challenge (EHPC).Methods and analysis Healthy adult participants aged 18–50 years will be randomised to receive PCV13, PPV23 or placebo and then undergo one or two EHPCs involving intranasal administration of SPN at 1-month post-vaccination with serotype 3 (SPN3) and 6 months with serotype 6B (SPN6B). …”
Get full text
Article -
405
Investigation of the effects of combined exercises and self-management education, with and without functional exercises, on pain and functional outcomes in patients with avascular necrosis of the femoral head: a protocol for a single-blind, randomised controlled trial with a parallel design and a 4 month follow-up
Published 2025-02-01Get full text
Article -
406
Safety, Tolerability, and Immunogenicity of the Invaplex<sub>AR-Detox</sub> <i>Shigella</i> Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial
Published 2025-01-01“…Methods: In a multi-center, randomized, double-blind, and placebo-controlled dose-escalation phase Ia/b trial, the safety, tolerability, and immunogenicity of three intramuscular vaccinations administered 4 weeks apart with 2.5 µg or 10 µg of Invaplex<sub>AR-Detox</sub> vaccine, alone or in combination with 0.1 µg of the dmLT adjuvant, will first be assessed in a total of 50 healthy Dutch adults (phase Ia) and subsequently in 35 healthy Zambian adults (phase Ib) aged 18–50 years. …”
Get full text
Article -
407
Access to electronic resources by visually impaired people
Published 2003-01-01Subjects: Get full text
Article -
408
The Taking Charge After Stroke (TaCAS) study protocol: a multicentre, investigator-blinded, randomised controlled trial comparing the effect of a single Take Charge session, two Take Charge sessions and control intervention on health-related quality of life 12 months after stroke for non-Māori, non-Pacific adult New Zealanders discharged to community living
Published 2017-06-01“…However, there is limited information on the generalisability and optimum dose of these interventions.Methods The Taking Charge After Stroke (TaCAS) study is a multicentre, investigator-blinded, randomised controlled trial recruiting 400 participants following acute stroke from seven hospitals in New Zealand. …”
Get full text
Article -
409
The Prevalence and Causes of Visual Impairment in Type 2 Diabetes Mellitus in Northeast China
Published 2020-01-01“…The primary causes of blindness and low vision were assessed by senior ophthalmologists. …”
Get full text
Article -
410
-
411
Prevalence, Risk Factors, and Causes of Visual Impairment in an Elderly Chinese Uygur Population in Southern Xinjiang
Published 2021-01-01“…Cataract is the leading cause of low vision and blindness.…”
Get full text
Article -
412
Anterior Segment Findings in Vitamin A Deficiency: A Case Series
Published 2015-01-01“…Vitamin A deficiency is a rare but vision threatening disorder in the developed world, which can lead to blindness for severe keratomalacia with cornea scarring and perforation or night blindness due to impaired dark adaptation. …”
Get full text
Article -
413
The Nonmydriatic Fundus Camera in Diabetic Retinopathy Screening: A Cost-Effective Study with Evaluation for Future Large-Scale Application
Published 2016-01-01“…Fundus images obtained with a nonmydriatic fundus camera could be considered an effective, cost-sparing, and feasible screening tool for the early detection of DR, preventing blindness as a result of diabetes.…”
Get full text
Article -
414
Visual impairment prevention by early detection of diabetic retinopathy based on stacked auto-encoder
Published 2025-01-01“…Abstract Diabetic retinopathy (DR) presents a significant concern among diabetic patients, often leading to vision impairment or blindness if left untreated. Traditional diagnosis methods are prone to human error, necessitating accurate alternatives. …”
Get full text
Article -
415
Reducing the risk of visual disability for children with juvenile idiopathic arthritis uveitis through disease surveillance: past and future challenges
Published 2025-01-01“…Abstract Childhood blindness significantly impacts development, education, employment, and mental health, creating burden for families and society. …”
Get full text
Article -
416
Uveitis associated with elevation of intraocular pressure – what is the optimal therapy?
Published 2023-12-01“…Uveitis is the fifth leading cause of blindness in developed countries. The ocular complications of uveitis are not only related to the inflammation itself but also result from glucocorticosteroid therapy, which is the mainstay of treatment. …”
Get full text
Article -
417
Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model
Published 2018-01-01“…In conclusion, our study suggests a possible treatment that can relieve progressive blindness and paralysis in an animal model of NMO through improvement of the inflammatory milieu.…”
Get full text
Article -
418
Comparison of Fully Convolutional Networks and U-Net for Optic Disc and Optic Cup Segmentation
Published 2025-01-01“…Glaucoma, the leading cause of irreversible blindness, must be diagnosed early and thus treated in time. …”
Get full text
Article -
419
Ivermectin as a promising therapeutic option for onchocerciasis‐associated epilepsy
Published 2025-02-01“…Abstract Onchocerciasis, commonly known as river blindness, is a neglected tropical disease caused by the parasite Onchocerca volvulus. …”
Get full text
Article -
420
A 5-Year Retrospective Review of Fungal Keratitis at Hospital Universiti Sains Malaysia
Published 2012-01-01“…Background. Corneal blindness from healed infected keratitis is one of the most preventable causes of monocular blindness in developing countries, including Malaysia. …”
Get full text
Article